“Life sciences and biotechnology are widely regarded as one of the most promising frontier technologies for the coming decades.” European Commission, Life Sciences and Biotechnology – A Strategy for Europe, 2002.
Despite the capital intensity of the industry, the growth rate of the biotechnology industry during the 1990s and the beginning of the 21st century has been impressive. Biotechnology has been at the center of important developments across the pharmaceutical, agrochemical, energy, and environmental sectors.
Why invest in Biotech patents?
• Biotechnology is one of the most research-intensive industries. Biotechnology companies generally invest a significantly higher proportion of their revenues than others in R&D often between 40% and 50%.
• Biotechnology companies are very capital-intensive and investments have a long payback period.
• Investors in biotechnology firms are well-versed in the centrality of patents in the industry and usually conduct a thorough due diligence prior to taking the decision to invest in a company.
• Investors seek to determine whether the company has freedom to operate, determining whether it can commercialize the product without infringing on the IP rights of others. This minimizes the risk of investing in a biotech company.
Looking to invest in this year’s key international patents in biotech?
Pay close attention to the leading emerging healthcare company, Propanc Health Group Corporation (PPCH) and their lead product, PRP. Their focus is developing new and proprietary treatments for cancer patients suffering from solid tumors with a target on pancreatic, ovarian, and colorectal cancers. PRP aims to prevent tumor recurrence and metastasis in tumors. Metastasis is the main cause of patient death from cancer and 80% of solid cancers are tumors.
“We are making new and exciting discoveries regarding the application of PRP in a clinical setting, which I firmly believe could become a breakthrough product that revolutionizes the way we treat cancer and reduces the threat of this killer disease for many different cancers,” said Dr Julian Kenyon, Propanc’s Chief Scientific Officer
Just last week, PPCH announced a few exciting updates on pending patent applications in both Australia and Spain:
• The recent Patent Cooperation Treaty (PCT) application, filed in November 2016 in Australia, titled “Proenzyme composition” is directed to a composition comprising trypsinogen and chymotrypsinogen. This targets specific weight ratios and certain dosage levels for the Company’s lead product, PRP. Filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries.
• Another patent filed in Spain of last year, titled “Cancer Treatment,” was updated with animal data. These data showed a reduced density in tumors from mice post-treatment. Since this success, a second application was filed with additional claims cancer in a subject by either reducing, or controlling the amount of cancer stem cells.
Be on the lookout for more updates regarding PPCH and their innovative patent research.
Other Biotech Companies in the News
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics announced last month the promotion of Curtis Hecht to Senior Vice President, Business and Corporate Development, and Jennifer McNealey to Vice President, Investor Relations and Strategy. “These promotions reflect the leadership role these key individuals have played in developing Calithera Biosciences into a fully integrated biotechnology company,” said Susan Molineaux.
Eyegate Pharmaceuticals, Inc. (EYEG) announced financial results for the three-month period ended September 30, 2016. The results included $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense to continue development of cross-linked thiolated hyaluronic acid (“CMHA-S”) for use as an ocular bandage film.
Cara Therapeutics, CARA, is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Dr. Derek Chalmers, President and CEO, presented a company overview at the 23 rdAnnual NewsMakers in the Biotech Industry Conference last September. Head to www.CaraTherapeutics for the webcast recording.
Gilead Sciences, Inc. (GILD) created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. They have slipped 4.70% over the past year, but with a market cap of $137.19 billion, strong cash flow, and an overall healthy fiscal position.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States